Exelixis
EXEL
#1608
Rank
HK$79.83 B
Marketcap
HK$285.25
Share price
-0.97%
Change (1 day)
53.81%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) Fails to deliver data

Key failure to deliver metrics for Exelixis:

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for Exelixis (EXEL) - 3 months history

Number of shares, 3 months chart

Biweekly Failures to deliver volume for Exelixis (EXEL) - since 2013

Volume in USD (price x number of shares), data since 2013

Exelixis (EXEL) Failure to deliver volume, Year over Year

Year Volume (Price x Shares) Change
2025HK$2.67 M-77.89%
2024HK$12.08 M86.29%
2023HK$6.48 M-41.81%
2022HK$11.14 M-31.9%
2021HK$16.36 M-20.71%
2020HK$20.64 M303.63%
2019HK$5.11 M-70.5%
2018HK$17.33 M8.82%
2017HK$15.92 M-17.35%
2016HK$19.27 M-75.68%
2015HK$79.23 M19.37%
2014HK$66.37 M258.49%
2013HK$18.51 M

FTD volume in the last 3 months for similar companies or competitors

Company FTD volume (3 months) FTD volume (1 year) Country
HK$0.18 BHK$0.27 B๐Ÿ‡ฌ๐Ÿ‡ง UK
HK$6.86 MHK$53.59 M๐Ÿ‡ซ๐Ÿ‡ท France
HK$0.10 BHK$0.17 B๐Ÿ‡บ๐Ÿ‡ธ USA
HK$0.18 BHK$0.50 B๐Ÿ‡บ๐Ÿ‡ธ USA
HK$97.9 MHK$0.29 B๐Ÿ‡บ๐Ÿ‡ธ USA
HK$16.63 MHK$0.20 B๐Ÿ‡บ๐Ÿ‡ธ USA
HK$32.79 MHK$0.34 B๐Ÿ‡บ๐Ÿ‡ธ USA
HK$0.04 MHK$0.77 M๐Ÿ‡บ๐Ÿ‡ธ USA
N/AHK$0.04 M๐Ÿ‡บ๐Ÿ‡ธ USA